Search results for "hepatocellular carcinoma."
showing 10 items of 690 documents
Focal nodular hyperplasia proceeds hepatocellular carcinoma in an adult with congenital absence of the portal vein
2012
Activation of tumor initiating cells during anti-angiogenic therapies promotes tumor progression and relapse formation in hepatocellular carcinoma
2016
Epidemiology, Risk Factors, and Natural History of Hepatocellular Carcinoma
2002
The incidence of hepatocellular carcinoma is increasing in many countries. The estimated number of new cases annually is over 500,000, and the yearly incidence comprises between 2.5 and 7% of patients with liver cirrhosis. The incidence varies between different geographic areas, being higher in developing areas; males are predominantly affected, with a 2:3 male/female ratio. The heterogeneous geographic distribution reflects the epidemiologic impact of the main etiologic factors and environmental risk, which are the hepatitis B (HBV) and hepatitis C (HCV) viruses. The percentage of cases of hepatocellular carcinoma attributable to HBV worldwide is 52.3% and is higher in Asia where the serop…
Waiting-time and quality of care deserved to patients with early stage hepatocellular carcinoma undergoing RFA treatment
2017
Alteration of the YY1/RKIP ratio is a frequent event in hepatocellular carcinoma
2009
Targeting NUPR1 with the Small Compound ZZW-115 Is an Efficient Strategy to Treat Hepatocellular Carcinoma
2020
International audience; HCC is a highly lethal malignancy with Sorafenib as the only molecularly targeted drug. The multifunctional stress-associated protein, NUPR1, plays an essential role in controlling cell growth, migration, invasion and Sorafenib resistance in HCC. We report here that NUPR1 expression is absent in healthy liver and it is progressively upregulated in HCC premalignant lesions such as hepatitis and cirrhosis with a maximum expression in HCC samples, highlighting that NUPR1 is a potential drug target for HCC. We therefore assessed in this work, ZZW-115, a strong inhibitor of NUPR1, as a promising candidate for the treatment of HCC. We validated its extraordinary antitumor …
Rapamycin and Zoledronic Acid strongly retard growth of advanced murine hepatocellular carcinoma via skewing and activation of innate and adaptive im…
2018
Etude des facteurs nutritionnels et métaboliques de la cancérogenèse hépatique chez des patients atteints de cirrhose
2019
Hepatocellular Carcinoma (HCC) is worldwide the 5th most common diagnosed cancer in men and the 7th in women and the 4th cause of cancer death with a median survival between 10 and 11 months. The incidence rate in France is relatively high (7.8/100 000 with 10 624 estimated new cases in 2018). HCC prognosis is very poor due to the difficulty to diagnose it at an early stage. Around 80% of HCC occur in the setting of cirrhosis, mainly caused by alcoholism, chronic infections with HBV and HCV or metabolic syndrome. Cirrhotic patients have a high-risk to develop chronic inflammation or other liver complications that can progress toward cancer. Thus, it is important to identify the risk factors…
Development of biosensors for detection of alpha-fetoprotein: As a major biomarker for hepatocellular carcinoma
2020
Abstract Alpha-fetoprotein as a multifunctional glycoprotein with a dual regulatory role in cancer and fetal activities is belonging to an albuminoid gene family. Due to important biological activities of alpha-fetoprotein in the adjustment of cancer, the level of this biomarker, majorly in liver carcinomas, abnormally is elevated. Also, the probability of high-risk or low-risk patients for chromosomal abnormalities can be identified by the serum level of alpha-fetoprotein. The detection of biomarkers possesses an important role in prognosis and early diagnosis of cancer and other diseases. So, the development of accurate and sensitive methods for measurement of alpha-fetoprotein is of grea…